DOCSLIB.ORG

Improving Predictability and Transparency in Dea and Fda Regulation

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Improving Predictability and Transparency in Dea and Fda Regulation IMPROVING PREDICTABILITY AND TRANSPARENCY IN DEA AND FDA REGULATION HEARING BEFORE THE SUBCOMMITTEE ON HEALTH OF THE COMMITTEE ON ENERGY AND COMMERCE HOUSE OF REPRESENTATIVES ONE HUNDRED THIRTEENTH CONGRESS SECOND SESSION APRIL 7, 2014 Serial No. 113–137 ( Printed for the use of the Committee on Energy and Commerce energycommerce.house.gov U.S. GOVERNMENT PUBLISHING OFFICE 90–872 PDF WASHINGTON : 2015 For sale by the Superintendent of Documents, U.S. Government Publishing Office Internet: bookstore.gpo.gov Phone: toll free (866) 512–1800; DC area (202) 512–1800 Fax: (202) 512–2104 Mail: Stop IDCC, Washington, DC 20402–0001 VerDate Mar 15 2010 13:37 May 11, 2015 Jkt 037690 PO 00000 Frm 00001 Fmt 5011 Sfmt 5011 F:\113-137 DEA, FDA REGS 2ND SCAN REQ 5-7-15\113-137 DEA, FDA REGS PENDING COMMITTEE ON ENERGY AND COMMERCE FRED UPTON, Michigan Chairman RALPH M. HALL, Texas HENRY A. WAXMAN, California JOE BARTON, Texas Ranking Member Chairman Emeritus JOHN D. DINGELL, Michigan ED WHITFIELD, Kentucky FRANK PALLONE, JR., New Jersey JOHN SHIMKUS, Illinois BOBBY L. RUSH, Illinois JOSEPH R. PITTS, Pennsylvania ANNA G. ESHOO, California GREG WALDEN, Oregon ELIOT L. ENGEL, New York LEE TERRY, Nebraska GENE GREEN, Texas MIKE ROGERS, Michigan DIANA DEGETTE, Colorado TIM MURPHY, Pennsylvania LOIS CAPPS, California MICHAEL C. BURGESS, Texas MICHAEL F. DOYLE, Pennsylvania MARSHA BLACKBURN, Tennessee JANICE D. SCHAKOWSKY, Illinois Vice Chairman JIM MATHESON, Utah PHIL GINGREY, Georgia G.K. BUTTERFIELD, North Carolina STEVE SCALISE, Louisiana JOHN BARROW, Georgia ROBERT E. LATTA, Ohio DORIS O. MATSUI, California CATHY MCMORRIS RODGERS, Washington DONNA M. CHRISTENSEN, Virgin Islands GREGG HARPER, Mississippi KATHY CASTOR, Florida LEONARD LANCE, New Jersey JOHN P. SARBANES, Maryland BILL CASSIDY, Louisiana JERRY MCNERNEY, California BRETT GUTHRIE, Kentucky BRUCE L. BRALEY, Iowa PETE OLSON, Texas PETER WELCH, Vermont DAVID B. MCKINLEY, West Virginia BEN RAY LUJAN, New Mexico CORY GARDNER, Colorado PAUL TONKO, New York MIKE POMPEO, Kansas JOHN A. YARMUTH, Kentucky ADAM KINZINGER, Illinois H. MORGAN GRIFFITH, Virginia GUS M. BILIRAKIS, Florida BILL JOHNSON, Ohio BILLY LONG, Missouri RENEE L. ELLMERS, North Carolina SUBCOMMITTEE ON HEALTH JOSEPH R. PITTS, Pennsylvania Chairman MICHAEL C. BURGESS, Texas FRANK PALLONE, JR., New Jersey Vice Chairman Ranking Member ED WHITFIELD, Kentucky JOHN D. DINGELL, Michigan JOHN SHIMKUS, Illinois ELIOT L. ENGEL, New York MIKE ROGERS, Michigan LOIS CAPPS, California TIM MURPHY, Pennsylvania JANICE D. SCHAKOWSKY, Illinois MARSHA BLACKBURN, Tennessee JIM MATHESON, Utah PHIL GINGREY, Georgia GENE GREEN, Texas CATHY MCMORRIS RODGERS, Washington G.K. BUTTERFIELD, North Carolina LEONARD LANCE, New Jersey JOHN BARROW, Georgia BILL CASSIDY, Louisiana DONNA M. CHRISTENSEN, Virgin Islands BRETT GUTHRIE, Kentucky KATHY CASTOR, Florida H. MORGAN GRIFFITH, Virginia JOHN P. SARBANES, Maryland GUS M. BILIRAKIS, Florida HENRY A. WAXMAN, California (ex officio) RENEE L. ELLMERS, North Carolina JOE BARTON, Texas FRED UPTON, Michigan (ex officio) (II) VerDate Mar 15 2010 13:37 May 11, 2015 Jkt 037690 PO 00000 Frm 00002 Fmt 0486 Sfmt 5904 F:\113-137 DEA, FDA REGS 2ND SCAN REQ 5-7-15\113-137 DEA, FDA REGS PENDING CONTENTS Page Hon. Joseph R. Pitts, a Representative in Congress from the Commonwealth of Pennsylvania, opening statement ................................................................... 1 Prepared statement .......................................................................................... 44 Hon. Frank Pallone, Jr., a Representative in Congress from the State of New Jersey, opening statement .......................................................................... 45 Hon. John D. Dingell, a Representative in Congress from the State of Michi- gan, opening statement ....................................................................................... 47 Hon. Fred Upton, a Representative in Congress from the State of Michigan, opening statement ................................................................................................ 47 Prepared statement .......................................................................................... 48 Hon. Marsha Blackburn, a Representative in Congress from the State of Tennessee, opening statement ............................................................................ 48 Prepared statement .......................................................................................... 66 Hon. Ed Whitfield, a Representative in Congress from the Commonwealth of Kentucky, opening statement ......................................................................... 67 Hon. Michael C. Burgess, a Representative in Congress from the State of Texas, opening statement .................................................................................... 67 Hon. Henry A. Waxman, a Representative in Congress from the State of California, opening statement ............................................................................. 68 WITNESSES Janet Woodcock, Director, Center for Drug Evaluation and Research, Food and Drug Administration, Department of Health and Human Services ......... 69 Prepared statement .......................................................................................... 72 Answers to submitted questions ...................................................................... 184 Joseph T. Rannazzisi, Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration, Department of Justice ............... 80 Prepared statement .......................................................................................... 82 Answers to submitted questions ...................................................................... 194 Nathan B. Fountain, Chair, Professional Advisory Board, Epilepsy Founda- tion of America ..................................................................................................... 122 Prepared statement .......................................................................................... 126 John M. Gray, President and Chief Executive Officer, Healthcare Distribution Management Association ..................................................................................... 134 Prepared statement .......................................................................................... 136 D. Linden Barber, Partner and Director, DEA Compliance and Litigation Practice, Quarles & Brady, LLP ......................................................................... 141 Prepared statement .......................................................................................... 143 Answers to submitted questions ...................................................................... 212 Wendy K.D. Selig, President and Chief Executive Officer, Melanoma Research Alliance ................................................................................................................. 155 Prepared statement .......................................................................................... 157 Scott Faber, Senior Vice President for Government Affairs, Environmental Working Group ..................................................................................................... 163 Prepared statement .......................................................................................... 165 SUBMITTED MATERIAL H.R. 4069, the Ensuring Patient Access and Effective Drug Enforcement Act of 2013, submitted by Mr. Pitts ................................................................... 2 H.R. 4250, the Sunscreen Innovation Act, submitted by Mr. Pitts ..................... 15 H.R. 4299, the Improving Regulatory Transparency for New Medical Thera- pies Act, submitted by Mr. Pitts ......................................................................... 41 (III) VerDate Mar 15 2010 13:37 May 11, 2015 Jkt 037690 PO 00000 Frm 00003 Fmt 5904 Sfmt 5904 F:\113-137 DEA, FDA REGS 2ND SCAN REQ 5-7-15\113-137 DEA, FDA REGS PENDING IV Page Letter of April 7, 2014, from Gina F. Adams, Corporate Vice President, Government Affairs, FedEx Corporation, to Mr. Upton, et al., submitted by Mrs. Blackburn ................................................................................................ 50 Statement of April 7, 2014, by the National Association of Chain Drug Stores, submitted by Mrs. Blackburn ............................................................................. 51 Letter of April 7, 2014, from Alliance to Prevent the Abuse of Medicines to Hon. Tom Marino and Mrs. Blackburn, submitted by Mrs. Blackburn ...... 64 Letter of April 4, 2014, from Brett M. Coldiron, President, American Academy of Dermatology Association to Mr. Pitts and Mr. Pallone, submitted by Mr. Whitfield ........................................................................................................ 108 Letter of April 7, 2014, from Bill Piper, Director, Office of National Affairs, Drug Policy Alliance, to Mr. Pitts and Mr. Pallone, submitted by Mr. Pallone .................................................................................................................. 120 Statement of April 7, 2014, by the Global Healthy Living Foundation, sub- mitted by Mr. Pitts .............................................................................................. 182 VerDate Mar 15 2010 13:37 May 11, 2015 Jkt 037690 PO 00000 Frm 00004 Fmt 5904 Sfmt 5904 F:\113-137 DEA, FDA REGS 2ND SCAN REQ 5-7-15\113-137 DEA, FDA REGS PENDING
Load more

Recommended publications
  • Senate Passage Media Clips Report September 19, 2014
    Senate Passage Media Clips Report September 19, 2014 1. The Hill, September 17, 2014, Senate passes bill to improve sunscreen. By Ramsey Cox 2. TIME, September 17, 2014, Senate Passes Bill for Better Sunscreen. By Alexandra Sifferlin 3. The Daily Caller, September 18, 2014, Senate Bill Passes To End FDA Stranglehold On Sunscreen Innovation. By Jonah Bennet 4. Skin, Inc. September 19, 2014, 2014 Sunscreen Innovation Act Unanimously Passes. 5. Inside Health (Subscription), September 18, 2014, Sunscreen Legislation Backers Seek Swift Enactment After Senate Clears Bill. By Stephanie Beasley 6. Politico Pulse (Subscription), September 18, 2014, Sunscreen bill heads to the House now. 7. Politico Pulse (Subscription), September 18, 2014, HELP approve sunscreen bill. 8. Office of Senator Kay Hagan, September 19, 2014, Bipartisan Sunscreen Innovation Act Cosponsored by Hagan Passes the Senate. 9. Northwest Georgia News, September 18, 2014, Isakson applauds Senate passage of bipartisan bill to help prevent skin cancer. 10. Primer{TBR}, September 18, 2014, Senate Passes Sunscreen Innovation Act to Improve Sunscreen. 11. Smithsonian, September 18, 2014, The US Is Trying to Expedite Sunscreen Innovation. By Rachel Nuwer 12. Cosmetics & Toiletries, September 18, 2014, Sunscreen Innovation Act Passes: What Does it Mean? By Rachel Grahenhofer 13. Office of Senator Mitch McConnell (Press Release), September 18, 2014, McConnell- Sponsored Sunscreen Innovation Act Passes Senate. 14. MarketPlace, September 18, 2014, Your sunscreen is way out of date. By Nancy Marshall-Genzer 37#32748001_v1 15. Earthy Essence, September 18, 2014, 2014 Sunscreen Innovation Act Unanimously Passes. 16. Melanoma Research Alliance, September 17, 2014, MRA Applauds Senate Passage of the Sunscreen Innovation Act.
    [Show full text]
  • GAO-18-61, SUNSCREEN: FDA Reviewed Applications For
    United States Government Accountability Office Report to Congressional Committees November 2017 SUNSCREEN FDA Reviewed Applications for Additional Active Ingredients and Determined More Data Needed GAO-18-61 November 2017 SUNSCREEN FDA Reviewed Applications for Additional Active Ingredients and Determined More Data Needed Highlights of GAO-18-61, a report to congressional committees Why GAO Did This Study What GAO Found Using sunscreen as directed with other The Food and Drug Administration (FDA), within the Department of Health and sun protective measures may help Human Services, implemented requirements for reviewing applications for reduce the risk of skin cancer—the sunscreen active ingredients within time frames set by the Sunscreen Innovation most common form of cancer in the Act, which was enacted in November 2014. For example, the agency issued a United States. In the United States, guidance document on safety and effectiveness testing in November 2016. sunscreen is considered an over-the- counter drug, which is a drug available As of August 2017, all applications for sunscreen active ingredients remain to consumers without a prescription. pending after the agency determined more safety and effectiveness data are Some sunscreen active ingredients not needed. By February 2015, FDA completed its initial review of the safety and currently marketed in the United States effectiveness data for each of the eight pending applications, as required by the have been available in products in act. FDA concluded that additional data are needed to determine that the other countries for more than a ingredients are generally recognized as safe and effective (GRASE), which is decade. Companies that manufacture needed so that products using the ingredients can subsequently be marketed in some of these ingredients have sought the United States without FDA’s premarket approval.
    [Show full text]
  • New Sunscreen Approval — Why So Complicated?
    Watch Pages New Sunscreen Approval — Why So Complicated? Topically-applied sunscreen product use is a billion-dollar These popular sunscreens have been submitted to the industry. The use of these products over the last 40 US Food and Drug Administration (FDA) over the last 15 years has changed dramatically from a “niche” market of years for approval. The FDA has approved none of these fair-skinned individuals who used small amounts on an products — which are regulated as drugs in the US — irregular basis to the current market of a large swath of despite years of use in Europe, Asia, or Latin America, the adult and paediatric population, fair-skinned or not, where they are regulated as cosmetics. The last over-the- over larger areas of their bodies on a much more regular counter (OTC) sunscreen approved by the FDA was in the basis — in some cases, daily. late 1990s. That said, the agency has not rejected these products either. Benefits of sunscreen use (SPF 15+) are widely accepted: sunburn prevention, skin-aging reduction, and, Instead, the products are in a nebulous regulatory of particular importance, skin cancer risk reduction. The area due to their classification and lack of criteria to benefits and increased usage have resulted in demand determine the type of clinical data needed to prove they for and development of a wide array of new sunscreen are “generally recognised as safe and effective” (GRASE), products over the last 20 years. These modern products an essential designation needed for OTC approval. This offer enhanced protection against the ultraviolet A (UVA) designation is usually granted, and the drug thereby rays that play a larger part in skin cancer than was once regulated, under what is called the OTC drug monograph believed, as well as the traditional protection against process.
    [Show full text]
  • Perspective: Protect the USA From
    OUTLOOK MELANOMA PERSPECTIVE Protect the USA from UVA The United States does not have access to the latest sunscreens. The Sunscreen Innovation Act could set that right, says Michael J. Werner. ccording to the Skin Cancer Foundation, more than 3.5 mil- pending sunscreen ingredients, the FDA argued that the approval lion skin cancers and 76,000 melanomas are diagnosed each in a comparable jurisdiction, such as the EU, and experience of safe year in the United States, and, on average, one person dies marketing is insufficient to support the approval of a sunscreen ingre- Afrom melanoma every hour. As with most diseases, the best way to dient in the United States. Rather, the FDA would like companies to fight melanoma is to prevent it. Unfortunately, the latest sunscreen perform additional safety testing unique to the United States. This ingredients that can help to reduce the risk of melanoma and other might include studies of dermal safety, ‘bioavailability’, carcinogenicity, skin cancers have languished for decades awaiting approval from the developmental and reproductive toxicity, and toxicokinetics. The FDA US Food and Drug Administration (FDA). acknowledged that some of these tests would take at least two years. The ultraviolet (UV) filters in sunscreen work by absorbing, reflect- The FDA’s sluggish regulatory response prompted the forma- ing or scattering the UV light emitted by the Sun. UVA radiation, tion of the Public Access to Sunscreens (PASS) Coalition in March which represents roughly 90% of UV radiation, can accelerate skin 2013, for which I am a policy adviser. The coalition’s mission is to ageing, cause skin damage and create a risk of skin cancer by damaging work with the FDA, Congress, the White House, health providers DNA.
    [Show full text]
  • Federal Register/Vol. 84, No. 38/Tuesday, February 26, 2019
    6204 Federal Register / Vol. 84, No. 38 / Tuesday, February 26, 2019 / Proposed Rules DEPARTMENT OF HEALTH AND the public. Similarly, if your submission 1978–N–0018 (formerly Docket No. HUMAN SERVICES includes safety and effectiveness data or FDA–1978–N–0038) for ‘‘Sunscreen information marked as confidential by a Drug Products for Over-the-Counter Food and Drug Administration third party (such as a contract research Human Use.’’ Received comments, those organization or consultant), you should filed in a timely manner (see 21 CFR Parts 201, 310, 347, and 352 either include a statement that you are ADDRESSES), will be placed in the docket [Docket No. FDA–1978–N–0018] (Formerly authorized to make the information and, except for those submitted as Docket No. FDA–1978–N–0038) publicly available or include an ‘‘Confidential Submissions,’’ publicly authorization from the third party viewable at https://www.regulations.gov RIN 0910–AF43 permitting the information to be or at the Dockets Management Staff between 9 a.m. and 4 p.m., Monday Sunscreen Drug Products for Over-the- publicly disclosed. If you submit data through Friday. Counter Human Use without confidential markings in response to this document and such • Confidential Submissions—To AGENCY: Food and Drug Administration, data includes studies or other submit a comment with confidential HHS. information that were previously information that you do not wish to be made publicly available, submit your ACTION: Proposed rule. submitted confidentially (e.g., as part of a new drug application), FDA intends to comments only as a written/paper SUMMARY: The Food and Drug presume that you intend to make such submission.
    [Show full text]
  • Information on FDA Regulation of Most OTC Drugs
    United States Government Accountability Office Report to the Congressional Committees July 2020 OVER­THE­ COUNTER DRUGS Information on FDA’s Regulation of Most OTC Drugs Accessible Version GAO-20-572 July 2020 GAO Highlights OVER-THE-COUNTER DRUGS Highlights of GAO-20-572, a report to Information on FDA’s Regulation of Most OTC Drugs congressional committees Why GAO Did This Study What GAO Found OTC drugs prevent and treat a The Food and Drug Administration (FDA) has regulated most over-the-counter variety of conditions; for example, (OTC) drugs—that is, drugs available without a prescription—through the OTC sunscreen is used to help prevent monograph process. FDA has described an OTC monograph as a "rulebook" for sunburn. FDA officials and marketing safe and effective OTC drugs, such as aspirin, cough and cold stakeholders, such as industry medicine, and hand sanitizer. OTC monographs established conditions—such as representatives and patient and active ingredients, indications for use, dosage forms, and product labeling— provider groups, have questioned under which an OTC drug was generally recognized as safe and effective. whether the monograph process used to regulate most OTC drugs According to FDA officials, before the CARES Act, which was enacted in March has been overly burdensome and 2020, the agency’s ability to update and finalize monographs in response to has limited FDA’s ability to quickly safety issues and to reflect new scientific information was limited by the update and finalize monographs in rulemaking process the agency was required to follow, as well as insufficient response to potential safety issues resources.
    [Show full text]
  • Enzacamene Order Based on This Proposed Order
    10026 Federal Register / Vol. 80, No. 37 / Wednesday, February 25, 2015 / Proposed Rules TABLE 11a—UNIQUE PERSONS OVER PERCENTAGES OF PROPOSED POSITION LIMIT LEVELS, JANUARY 1, 2013, TO DECEMBER 31, 2014—Continued Unique persons over level Commodity type/core referenced futures contract Percent of Spot month level (physical- Spot month Single month All months delivery) (cash-settled) 80 49 63 7 9 100 31 44 (*) 6 500 — 5 — — NYMEX RBOB Gasoline (RB) ............................................. 60 97 57 26 30 80 67 52 15 17 100 36 37 11 12 500 — (*) — — Metals COMEX Copper (HG) .......................................................... 60 12 — 61 62 80 9 — 37 40 100 4 — 29 30 COMEX Gold (GC) .............................................................. 60 13 — 22 24 80 9 — 14 14 100 5 — 10 11 COMEX Silver (SI) ............................................................... 60 9 — 34 32 80 4 — 20 21 100 (*) — 16 16 NYMEX Palladium (PA) ....................................................... 60 9 — 12 13 80 5 — 9 5 100 (*) — 4 4 NYMEX Platinum (PL) ......................................................... 60 11 — 29 29 80 7 — 18 18 100 (*) — 9 9 Legend: * means fewer than 4 unique owners exceeded the level. — means no unique owner exceeded the level. NA means not applicable.14 Both comment periods will reopen on DEPARTMENT OF HEALTH AND because the currently available data are February 26, 2015, and will close on HUMAN SERVICES insufficient to classify it as GRASE and March 28, 2015. not misbranded, and additional Food and Drug Administration information is needed to allow us to Issued in Washington, DC, on February 19, determine otherwise. 2015, by the Commission. 21 CFR Part 310 Christopher J. Kirkpatrick, DATES: Submit either electronic or [Docket Nos.
    [Show full text]
  • Congressional Record United States Th of America PROCEEDINGS and DEBATES of the 113 CONGRESS, SECOND SESSION
    E PL UR UM IB N U U S Congressional Record United States th of America PROCEEDINGS AND DEBATES OF THE 113 CONGRESS, SECOND SESSION Vol. 160 WASHINGTON, THURSDAY, NOVEMBER 13, 2014 No. 138 House of Representatives The House met at 10 a.m. and was man LUIS GUTIE´ RREZ, and others who mental in passing legislation to assist called to order by the Speaker pro tem- will be here. veterans exposed to Agent Orange. pore (Mr. BENTIVOLIO). Thank you, Congresswoman BUSTOS, But on the subject of posttraumatic f for bringing us together to honor the stress disorder and traumatic brain in- life and service and leadership of Lane jury, Lane had whatever symptoms he DESIGNATION OF SPEAKER PRO Evans, who passed away this month at had of his service to our country. TEMPORE the age of 63, my colleagues. As the ranking member, he traveled The SPEAKER pro tempore laid be- He was the ranking member on the the country. I had the privilege on a fore the House the following commu- Veterans’ Affairs Committee and number of occasions to welcome him at nication from the Speaker: served our veterans so well. He served Fort Miley, our veterans hospital in WASHINGTON, DC, our country in uniform. He served our San Francisco. The way he connected November 13, 2014. country in the Congress. He served our with the veterans, because he under- I hereby appoint the Honorable KERRY L. country in the community. He was just stood, he shared their pain—literally, BENTIVOLIO to act as Speaker pro tempore on a great person.
    [Show full text]
  • The Sunscreen Innovation
    Report to the World Health Organization International UV (INTERSUN) Project International Advisory Committee Country Report: United States of America (June 2018) The following activities are currently being undertaken in the USA: At the Centers for Disease Control and Prevention: Ongoing efforts to monitor and study relevant behaviors and health outcomes o Behaviors: use of sun protection, indoor tanning o Health outcomes: sunburn, melanoma incidence and mortality, Merkel cell carcinoma incidence and mortality Research to understand the effects of intervention strategies o Community-level interventions o Policies (e.g., restrictions on minors’ access to indoor tanning) o Projects to develop and test skin cancer prevention messages for various target audiences Efforts to promote and support a comprehensive, community-wide approach to skin cancer prevention o This includes skin cancer prevention work being done by CDC-funded Comprehensive Cancer Control programs in US states, tribes, and territories (https://www.cdc.gov/cancer/ncccp/) Further information about Skin Cancer: https://www.cdc.gov/cancer/skin/ At the Food and Drug Administration/Center for Drug Evaluation and Research: Helping to ensure the safety and effectiveness of sunscreens: The Sunscreen Innovation Act (SIA) was enacted on November 26, 2014 to provide an alternative process for the review of safety and effectiveness of nonprescription sunscreen active ingredients. FDA is currently using the SIA process to determine whether, and under what conditions of use, sunscreen products marketed in the United States may contain one or more of eight sunscreen active ingredients that are currently available more broadly in other countries but that can only be marketed in the United States with approved New Drug Applications (NDAs).
    [Show full text]
  • AN OVERVIEW of the FDA CHANGES to SUNSCREEN REGULATION in 2019 Cptclabs.Com
    AN OVERVIEW OF THE FDA CHANGES TO SUNSCREEN REGULATION IN 2019 cptclabs.com Sunscreens are routinely used by consumers for the prevention of sunburn and to reduce the risk of premature aging and skin cancer due to sun exposure. The American Academy of Dermatology (AAD), the Surgeon General, and the United States Food and Drug Administration (FDA) recommend that individuals use sunscreens as part of their daily sun protection plan, especially when engaged in outdoor activities. In the United States, sunscreens are regulated as over-the-counter (OTC) drugs under the FDA Final Rule 2011 [1], the Sunscreen Final Monograph 1999 [2] and the FDA Sunscreen Innovation Act (SIA) [3]. Under the Sunscreen Innovation Act, 21 USC 360-fff-5, enacted November 16, 2014, the FDA is required by law to finalize and put into effect the final monograph for OTC sunscreen products no later than November 26, 2019. THE CHANGES TO REGULATION IN 2019 On February 26, 2019, the FDA published a proposed rule, “Sunscreen Drug Products for Over-the-Counter Human Use [4]” to establish final monograph regulations for over-the-counter (OTC) sunscreen drug products. When finalized, the rule will inform the conditions required for OTC sunscreen products that are to be marketed in the United States. Within the proposed rule, the FDA provides its stance on the safety of active ingredients, dosage forms, SPF claims, broad spectrum claims, labeling, recordkeeping, and final formulation testing. HOW DOES THE PROPOSED RULE AFFECT ACTIVE INGREDIENTS IN SUNSCREENS? In the proposed rule, FDA states that there is still not enough evidence to determine the GRASE (Generally Recognized as Safe and Effective) status for most of the ingredients listed in the stayed 1999 final sunscreens rule.
    [Show full text]
  • Nonprescription Sunscreen Drug Products— Safety And
    Nonprescription Sunscreen Drug Products — Safety and Effectiveness Data Guidance for Industry U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) November 2016 OTC Nonprescription Sunscreen Drug Products — Safety and Effectiveness Data Guidance for Industry Additional copies are available from: Office of Communications, Division of Drug Information Center for Drug Evaluation and Research Food and Drug Administration 10001 New Hampshire Ave., Hillandale Bldg., 4th Floor Silver Spring, MD 20993-0002 Phone: 855-543-3784 or 301-796-3400; Fax: 301-431-6353 Email: [email protected] http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/default.htm U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) November 2016 OTC TABLE OF CONTENTS I. INTRODUCTION............................................................................................................. 1 II. PHARMACEUTICAL QUALITY/MANUFACTURING INFORMATION ............. 3 III. SAFETY DATA NEEDED TO ESTABLISH THAT AN OTC SUNSCREEN ACTIVE INGREDIENT IS GRASE ............................................................................... 4 A. Clinical Safety Testing ................................................................................................................... 5 1. Human Dermal Safety Studies ......................................................................................................... 5 a. Human irritation
    [Show full text]